Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 26, 2016Once-daily dose identified for the pivotal Phase 3 study
SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported positive top-line results from a Phase 2b clinical study of LPCN...
-
Sep 20, 2016
SALT LAKE CITY, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Aug 9, 2016
SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended June 30,...
-
Aug 4, 2016
SALT LAKE CITY, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
-
Jun 29, 2016
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter ("CRL") from the...
-
Jun 26, 2016
SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000® and Russell Global®...
-
May 9, 2016
SALT LAKE CITY, May 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended March 31,...
-
May 2, 2016
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO™ ("LPCN 1021"),...
-
Apr 6, 2016
SALT LAKE CITY, April 06, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Mar 28, 2016
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...